News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CN NMPA Approves Innovent Biologics' GLP-1 Weight Loss Drug for Marketing
China's National Medical Products Administration (NMPA) has recently approved the market launch of Innovent Biologics (Suzhou)'s Class 1 innovative drug Mazdutide injection...
Reset
Send
The window will close in 5 seconds
CN NMPA Approves Innovent Biologics' GLP-1 Weight Loss Drug for Marketing
Close
Recommend
2
Positive
6
Negative
0
 
SHORT SELL
 
STOCK INFO

China's National Medical Products Administration (NMPA) has recently approved the market launch of Innovent Biologics (Suzhou)'s Class 1 innovative drug Mazdutide injection.

This drug is a dual receptor agonist for glucagon and glucagon-like peptide-1 (GLP-1), indicated for long-term weight management in adult patients, in conjunction with dietary control and increased physical activity, who also have at least one weight-related comorbidity (such as hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome).

Related NewsBOCOMI Ratings, TPs on Pharmas (Table)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.